Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Frentz, Dineke ^a   Boucher, Charles A B ^a,b   Assel, Matthias ^c   de Luca, Andrea ^d,e   Fabbiani, Massimiliano ^d   Incardona, Francesca ^f   Libin, Pieter ^g   Manca, Nino ^h   Müller, Viktor ⁱ   Nualláin, Breanndán Ó ^j   Paredes, Roger ^k   Prosperi, Mattia ^d   Quiros Roldan, Eugenia ^h   Ruiz, Lidia ^k   Sloot, Peter M A ^j   Torti, Carlo ^h   Vandamme, Anne Mieke ^m   van Laethem, Kristel ^m   Zazzi, Maurizio ^l   van de Vijver, David A M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF STUTTGART   (Germany)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f Informa Srl   (Italy)

^g MyBioData ^*  (Belgium)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k Institut de Recerca de la SIDA irsiCaixa HIVACAT   (Spain)

^l UNIVERSITY OF SIENA   (Italy)

^m REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DIDANOSINE PLUS LOPINAVIR PLUS TENOFOVIR; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS LOPINAVIR PLUS TENOFOVIR; LAMIVUDINE PLUS LOPINAVIR PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; VIRUS LOAD; VIRUS MUTATION; ADOLESCENT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PHYSIOLOGY; STATISTICAL MODEL; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ROC CURVE; VIRAL LOAD; YOUNG ADULT;

EID: 77955385229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011505     Document Type: Article

References (20)

1. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, et al. (1999) Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 13: F17-F21.
2. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, et al. (1999) Drugresistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353: 2195-2199.
3. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, et al. (2002) Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). Aids 16: 369-379.
4. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, et al. (2002) Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. Aids 16: 209-218.
5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002) Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. Aids 16: 727-736.
6. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21: 215-223.
7. Liu TF, Shafer RW (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
8. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, et al. (2002) A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 7: 123-129.
9. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, et al. (2003) Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 187: 1934-1943.
10. Prosperi MC, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, et al. (2009) Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther 14: 433-442.
11. Sloot P, Coveney P, Bubak MT, Vandamme AM, B ON, et al. (2008) Multiscience decision support for HIV drug resistance treatment. Stud Health Technol Inform 138: 188-198.
12. Sloot PM, Coveney PV, Ertaylan G, Muller V, Boucher CA, et al. (2009) HIV decision support: from molecule to man. Philos Transact A Math Phys Eng Sci 367: 2691-2703.
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2008) Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 16: 138-145.
14. Hastie T, Tibshirani H, Friedman J (2001) The elements of statistical learning. New York, Springer.
15. Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, et al. (2009) Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother 64: 616-624.
16. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, et al. (2009) Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. J Infect Dis.
17. Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, et al. (2007) The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. Aids 21: 2033-2042.
18. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, et al. (2003) HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 33: 8-14.
19. Larder B, Wang D, Revell A, Montaner J, Harrigan R, et al. (2007) The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 12: 15-24.
20. Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, et al. (2004) Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 9: 465-478.